A novel molecular agent for glioma angiogenesis imaging

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Gliomas are rich in blood vessels and are the most primary and malignant type of brain tumor affecting the central nervous system. A few fluorine-18 (18F)-labeled imaging agents can be used for imaging of tumor angiogenesis. In the current study, 18F-labeled recombinant human endostatin (rh-endostatin) was developed and evaluated as a probe for PET imaging of tumor angiogenesis.

Materials and methods

18F-fluorobenzoyl-endostatin (18F-FB-endostatin) was synthesized from radiolabeling of rh-endostatin with N-succinimidyl-4-18F-fluorobenzoate produced by a facile module-assisted radiosynthesis procedure. Blocking studies were used to measure the relative affinities of 18F-FB-endostatin to human glioblastoma U87MG cells in tumor tissues rich with vessels. In addition, biodistribution, metabolic stability, and small-animal PET imaging studies were carried out with 18F-FB-endostatin using Institute of Cancer Research and U87MG tumor-bearing mice.

Results

Noninvasive small-animal PET imaging indicated that 18F-FB-endostatin showed rapid and good tumor uptake. The probe was rapidly cleared from the blood and most organs, resulting in excellent tumor-to-normal tissue contrasts. Tumor uptake and rapid clearance were further confirmed with biodistribution studies. Metabolite assays showed that the probe was highly stable, making it suitable for in-vivo applications.

Conclusion

18F-FB-endostatin shows promising in-vivo properties. Therefore, the promising properties of 18F-FB-endostatin indicate that this probe can be a powerful tool to evaluate the antiangiogenic therapy for gliomas and thus warrants further investigation as a novel PET probe for imaging of tumor angiogenesis.

Related Topics

    loading  Loading Related Articles